To evaluate incidence rates of and predictors for any antiretroviral (ART) drug discontinuation by HCV infection status in a large Italian cohort of HIV infected patients. All patients enrolled in ICONA who started combination antiretroviral therapy (cART) containing abacavir or tenofovir or emtricitabine or lamivudine plus efavirenz or rilpivirine or atazanavir/r or darunavir/r (DRV/r) or lopinavir/r or dolutegravir or elvitegravir or raltegravir were included. Multivariate Poisson regression models were used to determine factors independently associated with single ART drug discontinuation. Inverse probability weighting method to control for potential informative censoring was applied. Data from 10,637 patients were analyzed and 1,030 (9.7%) were HCV-Ab positive. Overall, there were 15,464 ART discontinuations due to any reason in 82,415.9 person-years of follow-up (PYFU) for an incidence rate (IR) of 18.8 (95% confidence interval [95%CI] 18.5-19.1) per 100 PYFU. No difference in IR of ART discontinuation due to any reason between HCV-infected and -uninfected patients was found. In a multivariable Poisson regression model, HCV-infected participants were at higher risk of darunavir/r discontinuation due to any reason (adjusted incidence rate ratio = 1.5, 95%CI 1.01-2.22, p value = 0.045) independently of demographics, HIV-related, ART and life-style factors. Among DRV/r treated patients, we found that HCV-viremic patients had twice the risk of ART discontinuation due to any reason than HCV-aviremic patients. In conclusion, HIV/HCV coinfected patients had a marginal risk increase of DRV/r discontinuation due to any reason compared with those without coinfection.
Introduction
The widespread use of combination antiretroviral therapy (cART) has substantially improved the prognosis of patients infected with HIV [1] . As a consequence of the reduction of AIDS-related events, non-HIV-related diseases now account for about half of all deaths [1, 2] . Chronic hepatitis C (CHC) is a leading cause of non-HIV-related mortality and morbidity among HIV-infected patients [3] . HIV coinfection with hepatitis C virus (HCV) has been associated with an increased risk of drug-related hepatoxicity in the first cART era [4] . Moreover, the extent of liver fibrosis in HIV-infected patients with CHC seems to be an important determinant of the risk of hepatotoxic events due to altered hepatic drug metabolism [5] . Additional data on the durability of different antiretroviral (ART) drugs according to the presence of HCV coinfection, in terms of overall ART discontinuation and long-term toxicities, and on the effect of HCV-treatment on the rate of ART discontinuation in HIV/HCV coinfected patients are needed [6, 7] . The aim of the study is to evaluate the incidence rates of and risk factors for discontinuation of different ART drugs due to any reasons and due to toxicity by HCV status in a large Italian cohort of HIV-infected patients.
Patients and methods

Study participants
The study population was selected from the Italian Cohort of Antiretroviral-Naïve patients (ICONA) Foundation Cohort Study. The ICONA study is an Italian multicenter prospective observational study of HIV-infected patients that was set up in April 1997. Study participants enrolled up to June 2016 were included. Clinical and laboratory data and data regarding any drug taken by the patient are collected for all participants and recorded using an electronic data collection form (www. iconafoundation.it). Patients are monitored for HCV status and tested regularly at least once a year when found to be HCV-Ab negative and results of the tests updated. All date of start and stop of each ART drugs are recorded together with the main reason for stopping as reported by the treating physician. All data are updated at the occurrence of any clinical event and in the absence of such an event, at least every 6 months. Details of the cohort and data collection have been previously reported [8] .
Inclusion criteria
All patients enrolled in ICONA who started cART defined as at least three ART drugs, including abacavir (ABC) or tenofovir (TDF) and emtricitabine (FTC) or lamivudine (3TC) plus efavirenz (EFV) or rilpivirine (RPV) or ritonavirboosted-atazanavir (ATV/r) or -darunavir (DRV/r) or --lopinavir (LPV/r) or dolutegravir (DTG) or elvitegravir/ cobicistat (EVG/COBI) or raltegravir (RAL) were included, regardless of whether this was their first cART regimen or not. Patients with hepatitis B infection at baseline were excluded from the analysis due to possible confounding factor for the analyses. In a sensitivity analysis we included only patients who started 3TC-based regimens after the year 2002.
Study endpoints
Although the main hypothesis is that HIV/HCV co-infected have an increased risk of stopping because of toxicity, because some of the stops due to toxicity are often classified as 'unknown' in cohort studies, we focused on two primary endpoints: ART drug discontinuation due to any reasons, and ART drug discontinuation due to any reasons except stopping for simplification or viral/immunological failure. As a secondary endpoint we restricted to ART drug discontinuation due to toxicity/intolerability. We both analyzed discontinuation of ≥1 drug in the regimen and the risk of stopping single drugs.
Definitions
ART drug discontinuations are recorded in the ICONA database according to a specified possible reasons for stopping which include the following: toxicity/intolerability, simplification, viral/immunological failure, non-adherence, and other reasons. These categories of discontinuation were defined as follows: toxicity/intolerability including stop due to ART adverse events or patient's intolerance; simplification including strategies to reduce pill burden or ART drugs in the regimen; viral/immunological failure including absence or partial viral/ immunological effectiveness of current ART drugs; nonadherence including ART drug intake <95% in the past 6 months. ART drug discontinuation due to toxicity/ intolerability was categorized into the following groups: liver, kidney, gastrointestinal (GI) tract, cardiovascular, central nervous system/peripheral nervous system (CNS/PNS), metabolism, hematology, other/unspecified. Dosage adjustments and structured treatment interruptions were not counted as discontinuations in this analysis. Discontinuations of fixed dose combination regimens were defined as events only if there was not a recorded re-starting date within a month of the date of stopping (e.g. no event was ascribed to FTC or TDF if Truvada was stopped and subsequently Atripla started within 30 days). AIDS diagnosis was defined using the 1993 Centers for Disease Control and Prevention criteria [9] . Liver fibrosis was defined using the FIB-4 score, and was calculated by Sterling's formula: age (years) × AST (U/l)/(platelets (109/ l) × (ALT (U/l)) 1/2 ). Advanced liver fibrosis was defined by a FIB-4 score > 3.25 [10] . Body mass index (BMI) was calculated according to a standardized definition as weight in kilograms divided by height in meters squared. Alcohol consumption was derived from three separate questions administered by treating physicians to the participants, regarding whether they use alcohol, what type of drinks and with which frequency/week, and was categorized as hazardous, moderate, abstaining and unknown. Hazardous drinking defined as >2-3 units/day for women and >3 units/day for men.
Statistical analysis
Characteristics of the study population at the time of starting one of the regimens including the specific aforementioned drugs (baseline) were described after stratification for HCVAb status into three groups as follows: (a) HCV-Ab negative Incidence of each ART discontinuation was expressed per 100 person-years of follow-up (PYFU). Exposure time period was defined as time from the date of starting the ART drug to the date of stopping the drug due to any reasons or to date the person was last seen if he/she did not discontinue. For each ART drug we fitted separate univariable and multivariable Poisson regression models to assess risk of drug discontinuation. A person could contribute person-years and events to more than one drug model. For example, someone who started on 3TC/ABC/EFV contributed to all three separate drug models for 3TC, ABC and EFV. Multivariable models were fitted only for drugs showing >100 events. Two separate approaches to analysis were used. In these analysis for specific reason of stopping, an inverse probability weighting (IPW) method to control for potential informative censoring was applied. To construct multivariable models we used the following sequence of adjustment for potential confounding factors: (a) Model #1: demographics (age, gender, ethnicity, region, mode of HIV transmission, calendar year of starting cART) plus metabolic factors (BMI and diabetes status), (b) Model #2: Model #1 plus HIV related factors (previous ART use, concomitant ART use, previous AIDS diagnosis, CD4 cell count, HIV-RNA viral load), (c) Model #3: Model 2 plus liver factors (FIB4 and alcohol use). Numerical variables were fitted either as continuous or categorical using pre-specified groups. For the endpoint of stopping due to any reason, all factors considered, including HCV infection exposure, were fitted as time-fixed using the values measured at baseline. In the analysis in which specific reasons for stopping have been considered, by means of the IPW approach and a Poisson matched for these weights to control for confounding, some time-varying factors (e.g. BMI, CD4 count, HIV-RNA) were fitted as time-dependent covariates. All analyses were performed using SAS (version 9.4, SAS Institute, Cary, North Carolina, USA).
Results
Study population
We included 10,637 patients, and among these, 1030 (9.7%) were HCV-Ab positive. Among patients with available information on HCV-RNA, 43% (217 out of 506) was positive and 14% (72 out of 506) was negative, respectively. Table 1 shows the main characteristics of the study population. In brief, the median age was 38 (IQR 32-46) years; 2593 (24%) patients were female; 1837 (17%) patients became HIV-infected through injection drug use (IDU), 4263 (40%) patients were infected through heterosexual contact, and 3773 (36%) through homosexual contact. HCV infected patients were more likely to be infected with HIV by IDU than those HCV uninfected individuals (69% versus 2%, respectively). Median (IQR) CD4+ cell count at cART initiation was 315 (170-459) cells/μl, and median (IQR) HIV-RNA was 4.64 (3.87-5.19 ) log 10 copies/ml. Median (IQR) calendar year of starting cART in HCV-infected and -uninfected patients was 2001 (1998-2011) and 2012 (2007-2014) , respectively ( Table 1) .
Overall ART discontinuation
Overall, there were 15,464 ART discontinuations due to any reasons in 82,415.9 PYFU for an incidence rate (IR) of 18.8 (95% confidence interval [95%CI] 18.5-19.1) per 100 PYFU. Overall, among HCV-infected and -uninfected patients there were 1,046 and 5,574 ART discontinuations in 4, 816.4 and 25, 982.1 PYFU, and 21.5 (95%CI 20.9-22.0) cases per 100 PYFU, respectively (p value = 0.71). The overall observed number of ART discontinuations due to any reason in viremic-and aviremic-HCV patients were 297 over 1292.9 PYFU and 84 over 479.3 PYFU, corresponding to an IR of 23.0 (95% CI 20.4-25.7) and 17.5 (95% CI 14.0-21.7) per 100 PYFU, respectively (p value = 0.03) ( Table S1 ). The most frequent causes of ART discontinuation due to any reason were: simplification (3401; 22%), toxicity/intolerability (2979; 19%), non-adherence (1720; 11%), viral/immunological failure (853; 6%), suspension (431; 3%), others (3344; 22%), and unknown (2736; 18%) ( Table 2 ). (Table S1 ). When investigating NRTI as a class, HCV infection was not associated with higher risk of NRTI discontinuations due to any reason after controlling for a number of potentially confounding factors (Table 3) . Similarly, viremic-HCV patients did not show an increased risk of ART discontinuation due to any reason compared to HCVAb positive but aviremic participants (Table S2) . when considered as the whole class due to any reason after controlling for a number of potentially confounding factors (Table 3) . Furthermore, no association between HCV-viremic infection and ART discontinuation was found (Table S2) . No difference between HCV-infected and -uninfected patients in ART discontinuation due to any reason except stopping for failure/simplification and due to toxicity/intolerability was found (Table S3 and S4). The most frequent causes of toxicity (360 out of 2092; 17%) were: CNS/PNS (26%), metabolism (21%), GI tract (14%), liver (7%), kidney (6%), hematology (3%), and other/unspecified toxicities (23%). No cardiovascular events leading to drug discontinuations were observed. In the unadjusted analysis, when only discontinuations due to liver causes were analyzed, HCV infection was not associated with an increased risk of EFV discontinuation (RR 1.04, 95% CI 0.02-10.51). Only one RPV liver-related discontinuation was observed.
Protease inhibitors (PIs)
There were 2,768 ART discontinuations due to any reason in 15, 930.5 PYFU (IR 17.4, . Among HCV-infected and -uninfected patients there were 139 and 1,024 ART discontinuations in 684. 5 and 5, 420 PYFU (IR 20.3, and IR 19.5, , per 100 PYFU, respectively; p value = 0.42). The overall observed number of ART discontinuations due to any reason in viremic-and aviremic-HCV patients were 62 over 229.2 PYFU and 19 over 120.8 PYFU, corresponding to an IR of 17.2 (95% CI 20.7-34.7) and 16.1 (95% CI 9.5-24.6) per 100 PYFU, respectively (p value = 0.03) (Table S1 ). HCV infection was associated with higher risk of DRV/r discontinuation due to any reason in model #2 (adjusted for demographics and HIV related factors) (aIRR 1.50, 95%CI 1.01-2.22, p value = 0.045) and was only marginally attenuated when controlling only for demographics (Model #1; aIRR 1.47, 95% 1.00-2.17, p value-= 0.053) ( Table 4) . Of note, when we grouped participants according to the results of HCV-RNA test, the magnitude of the effect was bigger and DRV/r was associated with a two-fold increased risk of ART discontinuation due to any reason in all models (aIRR 2. 1-3.8] in Model #3, respectively). HCV viremic infection was associated with higher risk of LPV/r discontinuation due to any reason in model #3 but not in other models (aIRR 1.67, 95%CI 1.01-2.76, p value 0.045) (Table S5) . No difference between HCV-infected anduninfected patients in ART discontinuation due to any reason except stopping for failure/simplification and due to toxicity/intolerability was found (Table S6 and S7). Among PI-treated patients, the following toxicities (582 out of 2768; 21%) were found: GI tract (26%), metabolism (18%), liver (11%), kidney (11%), CNS/PNS (6%), hematology (3%), cardiovascular (0.3%), and other/unspecified toxicities (24%). In an unadjusted analysis, when only discontinuations due to liver causes were analyzed, we found that HCV infection was associated with an increased risk of discontinuation of LPV/r (RR 7.19, 95% CI 1.55-36.23) but not of ATV/r (RR 1.42 95%CI 0. 15-6.64) . No DRV/r liver-related discontinuations were observed.
Integrase inhibitor (INIs)
The overall observed number of ART discontinuations due to any reason was 548 over 3149.9 PYFU, corresponding to an IR of per 100 PYFU. Among HCV-infected and -uninfected patients there were 24 and 235 ART discontinuations in 98. 7 and 1012.7 PYFU (IR 24.3, 95% CI 15.6-36.2, and IR 23.2, 95% CI 20.3-26.4 , per 100 PYFU, respectively; p value = 0.81). The overall observed number of ART discontinuations due to any reason in viremic-and aviremic-HCV patients were 11 over 51.8 PYFU and four over 27.5 PYFU, corresponding to an IR of 15.3 (95% CI 10.6-38.0) and 27.1 (95% CI 4.0-37.2) per 100 PYFU, respectively (p value = 0.54) (Table S1 ). HCV infection was not independently associated with higher risk of INI discontinuations due to any reason (Table 4) . With respect to single drugs, no association between HCV-viremic infection and the risk of RAL discontinuation was found. Risk of ELV-and DLGdiscontinuation was not estimable due to low number of events (Table S5) . Tables S6 and S7 show multivariable Poisson regression models for the other endpoints. Among INI-treated patients, the following toxicities (93 out of 548; 17%) were found: GI tract (27%), metabolism (17%), liver (13%), kidney (11%), CNS/PNS (11%), hematology (1%), cardiovascular (1%), and other/ unspecified toxicities (19%). In an unadjusted analysis, when only discontinuations due to liver causes were analyzed, we found that HCV infection was not associated with an increased risk of discontinuation of RAL (RR 2.88, 95% CI 0.05-35.89). No DTG or EVG liverrelated discontinuations were observed.
Discussion
In this analysis from the ICONA cohort, we evaluated the incidence and risk factors for ART discontinuation in HIV/ HCV coinfected patients compared to HIV monoinfected patients. Overall, we observed a total of 15,464 ART discontinuations due to any reason with the following frequency breakdown: simplification (22%), toxicity/intolerability (19%), 3 17.02 (11.54, 17.82) HCV-Ab negative 25 152. 1 16.44 (11.11, 24 .33) 1.00 1.00 1.00 1.00 HCV-Ab positive 2 6.08 32.88 (8.22, 131.5) 2.00 (0.46, 8.67) 2.10 (0.50, 8.82) 2.30 (0.57, 9.20) 2.58 (0.75, 8.83) non-adherence (11%), viral/immunological failure (6%), other/unknown (42%). When single ART drugs were analyzed, DRV/r was the only drug which showed evidence of an increased risk of ART discontinuation due to any reason among HCVinfected patients compared to those without HCV-infection. Specifically, HIV/HCV coinfected patients were found to have a 50% increased risk of ART discontinuation when adjusted for demographics plus HIV related factors. The magnitude of the effect was only marginally attenuated after controlling for other confounding factors, including life-style and previous and current history of cART.
Among DRV/r treated patients, we found that HCVviremic patients had twice the risk of ART discontinuation due to any reason than HCV-aviremic patients. These findings are consistent with those by Grint in EuroSIDA cohort who found that viremic HCVpositive patients had an increased risk of ART discontinuation due to toxicity or patient/physician choice compared to aviremic patients [11] .
Overall, we observed a low rate of ART discontinuation due to toxicity/intolerability. These results are in contrast with those of other studies published in early cART era where ART discontinuation accounted for about half of patients who started their first-line cART regimen [8] . These differences can be mainly explained by ART drugs that we investigated in this study. Indeed, in this analysis, we included only newer ART drugs while early studies included older ART regimens such as D-drug-or first-generation PI-containing regimens [12, 13] . Overall, our findings are consistent with those from recent observational studies, including the ICONA cohort study, where in recent years ART discontinuation is more likely due to ART simplification than due to toxicity [14, 15] .
In our cohort, we found a low rate of ART discontinuation due to hepatotoxicity that accounted for no more than 15% across all ART classes. These findings confirm the hepatic safety profile of most recently approved ART drugs and are consistent with those observed by others [16] .
In particular, HCV infection was not associated with an increased risk of DRV/r discontinuation due to toxicity compared to uninfected patients. In a previous ICONA analysis including 703 patients with or without HCV coinfection who started a DRV/r-containing regimen, viremic HCV patients did not show any severe (grade 3 and 4) liver enzyme elevations (LEEs) but experienced low grade LEEs more frequently than HCV-uninfected patients [17] .
Finally, we observed that advanced liver fibrosis, defined by a FIB-4 score > 3.25, was not associated with an increased risk of ART discontinuation due to toxicity/intolerability across all ART drugs evaluated. Advanced liver fibrosis is associated with an increased risk of hepatotoxicity in HIV/ HCV coinfected patients in some studies, but not in others [18, 19] . However, most of these studies have evaluated the rate of LEE but not rate of ART discontinuation in subjects with HCV coinfection [20] .
The major strengths of our study are that it is based on a large cohort of HIV-infected patients with a long follow-up and that we evaluated only newer ART drugs. Furthermore, we utilized a robust endpoint definition less likely to be prone to misclassification bias due to subjective reporting of the reason for stopping. However, when we used endpoint relying on the specific reason for stopping we have used IPW to account for potential informative of censoring (e.g. stopping due to failure is unlikely to be independent of stopping because of toxicity).
However, our study has also some limitations that need to be taken into account. For some of the drugs (EVG and DTG) we had a small number and/or a short time of follow-up. As a result there was a lack in power to detect differences in incidence rates of ART discontinuation. Another limitation is that although some biases could have been accounted for in the adjusted analyses in the different models, unmeasured confounding that we did not account for may still exist. In particular, we cannot exclude that clinicians have chosen potentially less hepatotoxic ART drugs for HCV infected patients supposed to be at higher risk of toxicity, introducing bias for indication. Finally, a general under-reporting of toxicity, as with all observational studies, is possible.
In conclusion, in our cohort, HIV/HCV coinfected patients had a marginal risk increase of DRV/r discontinuation due to any reason. Although this is likely to be due to toxicity of the drug when we used alternative endpoints trying to distinguish according to the reasons reported we found less evidence for a difference. These results warrant further investigations to better characterize the role of HCV infection as an independent prognostic factor for cART discontinuation and to determine how HIV/HCV-coinfected patients should be prioritized for HCV treatment.
